# Impact of Digital Therapeutic on Metabolic Parameters

Study · id `cardio:ct-nct04573296` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04573296](<https://clinicaltrials.gov/study/NCT04573296>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04573296

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT04573296. Randomized; no masking; primary purpose treatment. Start 2020-02-26 (actual); primary completion 2022-11-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT04573296, source copy `cardio:ctgov-nct04573296-2023-08-31`, retrieved 2026-10-26)
- Started: 2020-02-26 (actual) (ClinicalTrials.gov record NCT04573296, source copy `cardio:ctgov-nct04573296-2023-08-31`, retrieved 2026-10-26)
- Primary completion: 2022-11-30 (actual) (ClinicalTrials.gov record NCT04573296, source copy `cardio:ctgov-nct04573296-2023-08-31`, retrieved 2026-10-26)
- Completion: 2022-11-30 (actual) (ClinicalTrials.gov record NCT04573296, source copy `cardio:ctgov-nct04573296-2023-08-31`, retrieved 2026-10-26)
- Countries: Czechia (ClinicalTrials.gov record NCT04573296, source copy `cardio:ctgov-nct04573296-2023-08-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04573296-2023-08-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Impact of Digital Therapeutic on Metabolic Parameters
- Condition: Insulin Resistance
- Condition: Prediabetic State
- Condition: Diabetes Mellitus, Type 2
- Condition: Obesity
- Intervention (Device): Vitadio
- Intervention (Behavioral): Conventional high-intensity lifestyle intervention program
- Lead sponsor: Vitadio s.r.o.
- Lead sponsor class: INDUSTRY
- Collaborator: University Hospital Olomouc
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: University Hospital Olomouc (`cardio:org-university-hospital-olomouc`)

## Provenance

Content hash: ab2b0127b6afa8fe9b2e12d1355996ac64f11c688b2755473264af6317a6cbe9
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
